| Date: | 2010-05-07 |
| Biotech partner: | SynCo Bio Partners (the Netherlands) OncoMed Pharmaceuticals (USA) |
| Type of agreement: | * manufacturing |
| Compound: | antibodies |
| Nature of the agreement: | SynCo Bio Partners has expanded its current agreement with OncoMed Pharmaceuticals, a company developing novel therapeutics that target cancer stem cells. Under the expanded agreement, in addition to antibody OMP-21M18 (anti-DLL4 antibody), SynCo will fill batches of OncoMed’s investigational products, two additional antibodies in the OncoMed pipeline for use in Phase I and II clinical trials. SynCo will fill the OncoMed antibodies at its Amsterdam-based facility. |
